BMO Capital Reiterates Silence Therapeutics (SLN) at Outperform, 'expect a positive Pelacarsen readout to drive 100-200%+ upside"
Tweet Send to a Friend
BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $67.00 price target on Silence Therapeutics (NASDAQ: SLN).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
